Skip to main content
Article thumbnail
Location of Repository

Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1

By Erhard Kopetzki, Andreas Jekle, Changhua Ji, Eileen Rao, Jun Zhang, Stephan Fischer, Nick Cammack, Surya Sankuratri and Gabrielle Heilek


We describe a novel strategy in which two inhibitors of HIV viral entry were incorporated into a single molecule. This bifunctional fusion inhibitor consists of an antibody blocking the binding of HIV to its co-receptor CCR5, and a covalently linked peptide which blocks envelope mediated virus-cell fusion. This novel bifunctional molecule is highly active on CCR5- and X4-tropic viruses in a single cycle assay and a reporter cell line with IC50 values of 0.03–0.05 nM. We demonstrated that both inhibitors contribute to the antiviral activity. In the natural host peripheral blood mononuclear cells (PBMC) the inhibition of CXCR4-tropic viruses is dependant on the co-expression of CCR5 and CXCR4 receptors. This bifunctional inhibitor may offer potential for improved pharmacokinetic parameters for a fusion inhibitor in humans and the combination of two active antiviral agents in one molecule may provide better durability in controlling the emergence of resistant viruses

Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1997). CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.
    2. (2007). Delmedico MK: Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.
    3. (2004). DF: R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1. Journal of virology
    4. (2006). Dragic T: An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology
    5. (1999). Dragic T: Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Journal of virology
    6. (2007). DS: Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. Adv Pharmacol
    7. (2007). EA: HIV coreceptors: from discovery and designation to new paradigms and promise. European journal of medical research
    8. (2000). FS: Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. The Journal of cell biology
    9. (2007). Kuhmann SE: HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology
    10. (2007). Lazzarin A: Access denied? The status of co-receptor inhibition to counter HIV entry. Expert opinion on pharmacotherapy
    11. (2006). Lopalco L: Longlasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood
    12. (2002). MA: Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.
    13. (1997). NR: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1--infected individuals. The Journal of experimental medicine
    14. (2001). Olson WC: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of virology
    15. (2007). Perros M: Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitorbound receptor for entry. Journal of virology
    16. (2008). Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in HIV-1-Infected Patients.
    17. (1998). RA: A new classification for HIV-1. Nature
    18. (1998). RB: Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS (London,
    19. (1998). Saag MS: Potent suppression of HIV1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature medicine
    20. (2007). Sankuratri S: CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. Molecular pharmacology
    21. (2007). Sankuratri S: Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral research
    22. (2000). Siccardi AG: CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro.
    23. (2007). The role of receptors in the HIV-1 entry process. European journal of medical research
    24. (2001). W: Mechanisms of Synergy Between HIV-1 Attachment, Coreceptor and Fusion Inhibitors.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.